Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.

ABSTRACT:

Background

ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse-risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria. The therapeutic and prognostic impacts of hypomethylating agents (HMAs) and venetoclax in young adults with ASXL1-mutated AML is unclear.

Methods

Eighty-one patients with ASXL1-mutated AML ≤ 60 years old were retrospectively analyzed. The effects of HMAs plus venetoclax on treatment response and its prognostic value were compared with intensive chemotherapy (IC) and HMAs combined with low-intensity chemotherapy.

Results

Intensive chemotherapy independently predicted a worse treatment response (IC vs. HMA + venetoclax, OR = 0.183, 95% CI 0.048-0.693, p = 0

SUBMITTER: Cai Y 

PROVIDER: S-EPMC12272307 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature